LGI1 and Cognitive impairment: In a study pooling LGI1- and CASPR2-Ab positive cases, some form of cognitive impairment was detected in 28% of patients, with 9% showing a severe dementia at last follow-up using the clinical dementia rating scale (CDR ≥ 0.5) [60].